Consolidation therapy with high-dose cyclophosphamide (HDC) reduces minimal residual disease in patients with chronic lymphocytic leukemia (CLL) treated with fludarabine as induction therapy.

被引：0
|
作者：
Weiss, M [1 ]
Glenn, M [1 ]
Maslak, P [1 ]
Rahman, Z [1 ]
Megherian, L [1 ]
Noy, A [1 ]
Zelenetz, A [1 ]
Scheinberg, D [1 ]
Golde, D [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1911 / 1911
页数：1
相关论文
共 50 条
  • [21] THE ROLE OF GENETIC-BASED PROGNOSTIC FACTORS IN PREDICTING MINIMAL RESIDUAL DISEASE NEGATIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND OFATUMUMAB
    Raponi, S.
    Del Giudice, I.
    Ilari, C.
    Cafforio, L.
    Della Starza, I.
    De Propris, M. S.
    Nanni, M.
    Cavalli, M.
    De Novi, L. A.
    Mariglia, P.
    Mancini, F.
    Nardacci, M. G.
    Piciocchi, A.
    Albano, F.
    Specchia, G.
    Cuneo, A.
    Fabris, S.
    Neri, A.
    Vignetti, M.
    Mauro, F. R.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 12 - 12
  • [22] FLUDARABINE PLUS THALIDOMIDE AS FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Ailawadhi, S.
    Miller, K. C.
    Depaolo, D.
    Whitworth, A.
    Brady, W.
    Czuczman, M.
    Bernstein, Z. P.
    Hernandez-Ilizaliturri, F.
    Padmanabhan, S.
    Chanan-Khan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 34 - 34
  • [23] Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab improves the quality of response in patients with previously untreated chronic lymphocytic leukemia.
    Weiss, MA
    Lamanna, N
    Gencarelli, A
    Scheinberg, DA
    Maslak, PG
    Horgan, D
    BLOOD, 2002, 100 (11) : 365B - 365B
  • [24] Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH).
    Dufour, Annika
    Bohlander, S. K.
    Spiekermann, Karsten
    Schneider, Stephanie
    Braess, Jan
    Kakadiya, Purvi
    Mundt, Kirsten E.
    Smith, Helen
    Lin, Ming
    Barrett, Martin
    Hurst, Deborah
    Dmoszynska, Anna
    Bence-Bruckler, Isabelle
    Afanasiev, Boris V.
    Catalano, John
    Montillo, Marco
    Geisler, Christian H.
    Moiseev, Sergey I.
    Solal-Celigny, Philippe
    Robak, Tadeusz
    Hiddemann, Wolfgang
    BLOOD, 2010, 116 (21) : 598 - 598
  • [25] Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Al-Sawaf, Othman
    Seymour, John F.
    Kater, Arnon P.
    Fischer, Kirsten
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 775 - 791
  • [26] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wang, Xuemei
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Lerner, Susan
    Kantarjian, Hagop
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2085 - 2093
  • [27] Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
    Montillo, M
    Tedeschi, A
    Miqueleiz, S
    Veronese, S
    Cairoli, R
    Intropido, L
    Ricci, F
    Colosimo, A
    Scarpati, B
    Montagna, M
    Nichelatti, M
    Regazzi, M
    Morra, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2337 - 2342
  • [28] Alemtuzumab as consolidation therapy after fludarabine, cyclophosphamide and rituximab regimen (FC-R) for the treatment of young patients with chronic lymphocytic leukemia
    Gonnella, F.
    Carola, A.
    Esposito, M.
    Improta, S.
    Lucania, A.
    Villa, M. R.
    Mastrullo, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 40 - 40
  • [29] High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
    Mauro, Francesca R.
    Molica, Stefano
    Soddu, Stefano
    Ilariucci, Fiorella
    Coscia, Marta
    Zaja, Francesco
    Angelucci, Emanuele
    Re, Francesca
    Liberati, Anna Marina
    Tedeschi, Alessandra
    Reda, Gianluigi
    Pietrasanta, Daniela
    Gozzetti, Alessandro
    Battistini, Roberta
    Del Poeta, Giovanni
    Musolino, Caterina
    Nanni, Mauro
    Piciocchi, Alfonso
    Vignetti, Marco
    Neri, Antonino
    Albano, Francesco
    Cuneo, Antonio
    Del Giudice, Ilaria
    Della Starza, Irene
    De Propris, Maria Stefania
    Raponi, Sara
    Guarini, Anna R.
    Foa, Robin
    HAEMATOLOGICA, 2020, 105 (11) : 2671 - 2674
  • [30] ABSENCE OF MINIMAL RESIDUAL DISEASE DETECTABLE BY FACS, SOUTHERN BLOT OR PCR IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA TREATED WITH FLUDARABINE
    RICHARDSON, DS
    JOHNSON, SA
    HOPKINS, JA
    HOWE, D
    PHILLIPS, MJ
    ACTA ONCOLOGICA, 1994, 33 (06) : 627 - 630
12345